Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology Convergence 2022 Pharmaceutical Investing
Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts Pharmaceutical Investing
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection Pharmaceutical Investing
Johnson & Johnson Opens State-of-the-Art Science and Technology Campus in San Francisco Bay Area Pharmaceutical Investing
Aurinia Announces European Commission Approval of LUPKYNIS® for the Treatment of Lupus Nephritis Pharmaceutical Investing
Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union Life Science Investing News
AbbVie Secures Positive CHMP Opinion for Risankizumab for the Treatment of Adults with Moderate to Severe Crohn's Disease Pharmaceutical Investing
Late-Breaking Data Show Breadth of Abbott's Minimally Invasive Structural Heart Technologies Pharmaceutical Investing
Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1% Pharmaceutical Investing
